Probiotic Nasal Microbiome Augmentation for S. aureus Decolonization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current strategies for decolonizing Staphylococcus aureus from the nasal cavity lack long-term effectiveness and may select for multidrug-resistant strains or disrupt the endogenous microbiota, highlighting a need for alternative methods that effectively control S. aureus colonization without these drawbacks.
Innovation Solution
The use of probiotic organisms such as Dolosigranulum and Simonsiella species, administered intranasally, either alone or in combination with antibiotics like mupirocin, to reduce and prevent S. aureus colonization by modifying the nasal microbiome composition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics like mupirocin are used to decolonize S. aureus from the nasal cavity, then S. aureus colonization is reduced, but multidrug-resistant strains may be selected for
Solution Approach 1:
The patent introduces probiotic organisms (Dolosigranulum and Simonsiella species) as intermediary agents that mediate the decolonization process. These probiotics compete with S. aureus for colonization sites and resources, indirectly reducing S. aureus abundance without directly killing it, thereby avoiding the selection pressure that leads to multidrug-resistant strains while still achieving effective decolonization
2Reliability
If antibiotics are used to decolonize S. aureus from the nasal cavity, then S. aureus colonization is reduced, but the endogenous microbiota may be disrupted
Solution Approach 1:
The patent uses probiotic organisms as intermediary agents that selectively target S. aureus through competition for colonization sites and resources. This approach reduces S. aureus abundance while preserving the overall structure and function of the endogenous microbiota, as the probiotics integrate into the existing microbial community rather than indiscriminately eliminating all bacteria
Solution Approach 2:
The patent converts the potential harm of antibiotic use (microbiota disruption) into a benefit by using probiotic organisms that actively promote a favorable nasal microbiome. The probiotics not only reduce S. aureus colonization but also enhance the stability and resilience of the endogenous microbiota, turning a previously harmful approach into a beneficial one
3Object-affected harmful factors
If probiotic organisms are used to reduce S. aureus colonization, then multidrug resistance and microbiota disruption are avoided, but long-term effectiveness needs to be established
Solution Approach 1:
The patent employs probiotic organisms that establish continuous colonization in the nasal cavity, providing ongoing competitive pressure against S. aureus. This continuous presence of probiotics ensures sustained reduction of S. aureus colonization over time, addressing the need for long-term effectiveness while avoiding the harmful effects associated with intermittent antibiotic use
Solution Approach 2:
The patent leverages the feedback mechanism where probiotic colonization reduces S. aureus abundance, which in turn creates more ecological niche for probiotic proliferation. This positive feedback loop reinforces the decolonization effect over time, ensuring long-term effectiveness without requiring continuous external intervention or selecting for resistance
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces S. aureus colonization by promoting a favorable nasal microbiome, potentially offering long-term solutions without the risks of multidrug resistance or microbiota disruption, as evidenced by the predictive relationships between these probiotics and S. aureus abundance.
Implementation Method 1
The use of probiotic organisms such as Dolosigranulum and Simonsiella species, administered intranasally, either alone or in combination with antibiotics like mupirocin, to reduce and prevent S. aureus colonization by modifying the nasal microbiome composition.
Data Source
AI summary
Embodiments of the invention provide a method of reducing colonization of a subject's anterior nares and/or nasal cavity by a microorganism (e.g., Staphylococcus aureus). In some aspects, the method may include administering a pharmaceutical composition to the subject, wherein the pharmaceutical composition comprises a therapeutically effective amount of at least one probiotic.